News

Jul 28, 2022 Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers

Jun 02, 2022 Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

May 18, 2022 Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

May 09, 2022 Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

Apr 27, 2022 Atossa Therapeutics to Present at the Q2 Investor Summit Conference

Apr 20, 2022 Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

Mar 23, 2022 Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

Mar 08, 2022 Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

Feb 28, 2022 Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

Jan 27, 2022 Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

<< < > >>